智通财经APP获悉，据港交所2月12日披露，苏州引航生物科技股份有限公司(简称：引航生物)向港交所主板递交上市申请，华泰国际为其独家保荐人。 公司简介 招股书显示，引航生物是以技术创新为驱动的合成生物学引领者，致力于提供绿色可持续、高效生产且具备突出成本优势的生物基产品。公司的产品已在相 关市场占据领先地位。 就原料药及中间体而言，根据灼识咨询，自2025年实现氟苯尼考的规模化生产后，以截至2025年9月30日止九个月的收入计，公司于同期的市场份额为 24.5%，位居全球氟苯尼考行业第二位；以截至2025年9月30日止九个月的收入(包括内部及外部销售)计算，公司的D-乙酯市场份额44.5%，位居全球D-乙酯 行业排名第一。 为支持产品创新与商业化，引航生物已构筑起"双引擎"研发能力，包括突破性原创工艺路线设计能力及基于AI辅助与高通量DBTL工作流程的高效合成生物 学工程化能力。原创工艺路线设计为目标化合物的开发奠定有商业可行性的适宜技术路径，而高效的合成生物学工程化能力可在实验室快速完成酶及菌株改 造，并推动规模化生产。这两者结合在一起，使公司能够持续开发出有竞争力的产品并保持高速增长。 引航生物的产品开发 ...

据港交所2月12日披露，苏州引航生物科技股份有限公司(简称：引航生物)向港交所主板递交上市申请，华泰国际 为其独家保荐人。招股书显示，引航生物是以技术创新为驱动的合成生物学引领者，致力于提供绿色可持续、高 效生产且具备突出成本优势的生物基产品。公司的产品已在相关市场占据领先地位。就原料药及中间体而言，根 据灼识咨询，自2025年实现氟苯尼考的规模化生产后，以截至2025年9月30日止九个月的收入计，公司于同期的市 场份额为24.5%，位居全球氟苯尼考行业第二位；以截至2025年9月30日止九个月的收入(包括内部及外部销售)计 算，公司的D-乙酯市场份额44.5%，位居全球D-乙酯行业排名第一。 Suzhou Leadsynbio Technology Co., Ltd. 蘇州引航牛物科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) [编纂] 獨家保薦人、[编纂] [编纂]項下[编纂]數目 : [編纂]股H股(視乎[编纂]行使與否而定) [编纂]數目 [编纂]股H股(可予重新分配) : [编纂]數目 [编纂]股H股(可予重新分配及視乎[编纂]行使與否 : 而定) 最高[编纂] 每股[編纂]港元,另加 ...

全年共发生731 起融资事件，较2024年同比大幅增长 31%；涉及融资金额约593.78亿元人民币，同比增长 17%；平均单笔融资额达 8213 万元人民币，资 金配置效率稳步提升。 回顾近五年行业融资轨迹，2021 年堪称行业 "黄金峰值期"—— 受益于新冠疫情催化的疫苗及生物技术研发热潮，叠加科创板、港交所新政释放的政策红 利，资本市场对创新药赛道的追捧推动行业融资额攀升至1348.57亿元的历史高点。 然而，2022-2023 年行业进入深度调整期：一方面受资本市场整体寒冬影响，风险投资趋于保守；另一方面，创新药在医保谈判中面临超预期的价格降 幅，商业化前景的不确定性进一步抑制了资本投入，融资额连续两年下滑，2023年降至 570.04 亿元。 博远资本创始合伙人陶峰认为："创新药研发，归根到底是拼试错效率。中国创新药企当前的效率，从时间维度上讲是历史最强，从空间维度上看是全球 最强，这是毫无疑问的。成本、速度、质量，是创新药研发的三个关键。二十年前中国的质量和国际水平有差距，今天基本一致，同时成本低很多，这是 我们的核心优势。" 当资本市场的目光从"追热点" 转向 "看价值"，生物医药行业在2025 ...

Core Viewpoint - Watson Bio has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund, with a target size of 1 billion yuan, where the company will contribute 450 million yuan, accounting for 45% of the fund [1] Group 1: Investment Fund Details - The fund is initiated in collaboration with Guotou Chuangyi Industrial Fund Management Co., Ltd. and other parties [1] - The core investment focus of the fund is on synthetic biology, biomanufacturing, and biotechnology-related industries [1] Group 2: Strategic Implications - The establishment of the fund allows the company to closely engage with high-quality targets in the relevant fields [1] - This initiative is expected to provide rare opportunities for direct collaboration with target enterprises, laying the foundation for future industrial synergy and strategic mergers and acquisitions [1]

Core Viewpoint - The recent release of three group standards for astaxanthin production by Nanjing University of Technology marks a significant step in standardizing production technology in China, providing essential technical support for high-quality industry development [2][6]. Group 1: Standards Overview - The three standards include: 1. "Technical Requirements for the Production of Natural Astaxanthin for Health Foods," which outlines raw material selection, production processes, quality control, and safety evaluations to ensure compliance with food safety and efficacy requirements [12]. 2. "Quality Grade Evaluation of Natural Astaxanthin Raw Materials for Health Foods," which establishes quality grading standards for natural astaxanthin in health food applications, promoting high-quality industry development [12]. 3. "Technical Requirements for the Microbial (Red Yeast) Fermentation Method for Synthesizing Natural Astaxanthin," which provides systematic regulations covering strain selection, fermentation processes, extraction, purification, and product testing to promote green and efficient production technologies [12]. Group 2: Market Potential and Applications - Astaxanthin, a potent antioxidant, is widely used in health foods, cosmetics, and aquaculture, with increasing demand for natural products expected to drive market growth. The market size for astaxanthin is projected to reach $3.4 billion by 2027 [7]. - The successful heterologous synthesis of (S)-astaxanthin by the research team has achieved a yield of 0.9 g/L, and through adaptive evolution, a yeast strain has been developed that produces 4.6 times more astaxanthin at 25°C compared to the original strain [9]. - Various products have been developed for market release, including fish feed, carotenoid essential oils, pet snacks, and probiotics, facilitating the industrial application of this technology across multiple sectors [9].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | | --- | ...

Core Viewpoint - The company is undergoing a green transformation focused on low-carbon production and innovative green processes, leveraging synthetic biology and AI for future-oriented research and development [1] Group 1: Green Transformation - The company has established five production bases recognized as national or provincial green factories, with multiple processes included in the green low-carbon directory [1] - Significant reductions in energy and material consumption have been achieved through the transformation of green processes such as continuous and microchannel reactions [1] - The company has increased the proportion of green electricity through solar power generation and has implemented energy-saving upgrades and equipment renewal, as well as measures for water recycling and waste heat recovery, directly lowering operational and production costs [1] Group 2: New Quality Production Capacity - The company is one of the earliest developers of bio-fermentation pesticides in China, such as abamectin, and is proactively establishing synthetic biology laboratories and AI innovation platforms (Deyanzhichuang) [1] - Collaborations with industry giants like BASF and partnerships with top research institutions and advanced biotechnology companies aim to innovate from the source, developing the next generation of efficient and low-residue green pesticides [1]

Core Viewpoint - Watson Bio (300142.SZ) announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund, with a target size of 1 billion yuan, to focus on synthetic biology, biomanufacturing, and biotechnology sectors [1] Group 1: Investment Details - The board of directors approved the partnership agreement with Guotou Chuangyi Industrial Fund Management Co., Ltd., Yuxi State-owned Capital Operation Co., Ltd., and Central Enterprise Rural Industry Investment Fund Co., Ltd. [1] - Watson Bio will contribute 450 million yuan as a limited partner in the fund [1] Group 2: Strategic Implications - The investment aligns with national bio-economy development plans, creating multiple opportunities for the company to capture industry benefits [1] - The collaboration with Guotou Chuangyi will enable the company to rapidly expand business channels and access high-quality market opportunities and partners [1] - Direct participation in fund operations will allow the company to engage closely with quality targets in the relevant fields, facilitating strategic mergers and acquisitions [1]

Core Viewpoint - Watson Bio (300142.SZ) has announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners, aiming for a target size of 1 billion yuan, with the company contributing 450 million yuan as a limited partner [1] Group 1: Investment Fund Details - The fund's target size is set at 1 billion yuan [1] - Watson Bio will invest 450 million yuan of its own funds as a limited partner [1] - The fund will focus on various investment areas including synthetic biology, life and health, biological agriculture, bioenergy, biomaterials, technology platform enterprises, and high-throughput equipment [1] Group 2: Investment Areas - Investment areas include synthetic biology such as enzyme preparations, amino acids, and probiotics [1] - Life and health investments will cover plant extracts, recombinant collagen, sweeteners, and protein drugs [1] - Biological agriculture will focus on feed protein, micro-ecological preparations, animal vaccines, and biological nitrogen fixation [1] - Bioenergy investments will include bioethanol and biodiesel [1] - Biomaterials will focus on PLA, PHA, and PDO [1] - The fund will also target technology platform enterprises like strain development and AI protein design [1] - High-throughput equipment investments will include microfluidic devices and gene sequencing equipment [1]

Group 1 - Watson Bio announced the establishment of the Yunnan Chuangwo Biological Industry Investment Fund in collaboration with several partners [1] - The target scale of the fund is 1 billion yuan, with Watson Bio contributing 450 million yuan as a limited partner [1] - The fund will primarily invest in the synthetic biology manufacturing industry, including sectors such as synthetic biology, health and wellness, bio-agriculture, bio-energy, bio-materials, and technology platform enterprises [1]